Structure of Obatoclax
CAS No.: 803712-67-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Obatoclax, a Bcl-2 homology domain-3 mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 μMol/L), including Mcl-1 (IC50, 2.9 μMol/L) and Bfl-1 (IC50, 5 μMol/L).
Synonyms: GX15-070
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 803712-67-6 |
Formula : | C20H19N3O |
M.W : | 317.38 |
SMILES Code : | COC1=CC(C(N2)=CC3=C2C=CC=C3)=N/C1=C\C4=C(C)C=C(C)N4 |
Synonyms : |
GX15-070
|
MDL No. : | MFCD09833233 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
H460 NSCLC cells | 500 nM | 6, 24, 48 hours | Obatoclax disrupts BAK/MCL-1 complex | PMC3032298 |
AML ROS-low cells | 10µM | Inhibited oxidative respiration | PMC3595363 | |
5637 cells | 28 nM (IC50) | 1, 3, 5 days | Obatoclax inhibits cell proliferation and clonogenicity, and promotes apoptosis in a dose-dependent manner | PMC6470498 |
TCCSuP cells | 70 nM (IC50) | 1, 3, 5 days | Obatoclax inhibits cell proliferation and clonogenicity, and promotes apoptosis in a dose-dependent manner | PMC6470498 |
T24 cells | 20 nM (IC50) | 1, 3, 5 days | Obatoclax inhibits cell proliferation and clonogenicity, and promotes apoptosis in a dose-dependent manner | PMC6470498 |
TFK-1 | 0.5 μM | 16 hours | Obatoclax induced minimal apoptosis alone; however, it increased apoptosis 3- to 13-fold in all three cancer cell lines when combined with Apo2L/TRAIL. | PMC2562222 |
KMBC | 0.5 μM | 16 hours | Obatoclax induced minimal apoptosis alone; however, it increased apoptosis 3- to 13-fold in all three cancer cell lines when combined with Apo2L/TRAIL. | PMC2562222 |
KMCH | 0.5 μM | 16 hours | Obatoclax induced minimal apoptosis alone; however, it increased apoptosis 3- to 13-fold in all three cancer cell lines when combined with Apo2L/TRAIL. | PMC2562222 |
AML CD34+ progenitor cells | 250 nM - 10 μM | 24 hours | Obatoclax induced apoptosis in AML CD34+ progenitor cells with an average IC50 of 3.59 μM. | PMC4096127 |
KTC-1 cells | 1 µM to 10 µM | 24 hours | Obatoclax induced massive apoptosis of KTC-1 cells in a dose-dependent manner, and caused loss of mitochondrial membrane potential, dysfunction of mitochondrial respiration, reduction of cellular glycolysis, autophagy, neutralization of lysosomes, and caspase-related apoptosis. | PMC5381260 |
BCPAP cells | 1 µM to 10 µM | 24 hours | Obatoclax induced massive apoptosis of BCPAP cells in a dose-dependent manner, and caused loss of mitochondrial membrane potential, dysfunction of mitochondrial respiration, reduction of cellular glycolysis, autophagy, neutralization of lysosomes, and caspase-related apoptosis. | PMC5381260 |
K1 cells | 1 µM to 10 µM | 24 hours | Obatoclax induced massive apoptosis of K1 cells in a dose-dependent manner, and caused loss of mitochondrial membrane potential, dysfunction of mitochondrial respiration, reduction of cellular glycolysis, autophagy, neutralization of lysosomes, and caspase-related apoptosis. | PMC5381260 |
Karpas-422 cells | 100 nM | 24 hours | Obatoclax in combination with VSV activated the mitochondrial apoptotic pathway in Karpas-422 cells, leading to caspase-3 and -9 cleavage, cytochrome c release, and BAX translocation. | PMC2997588 |
CD5+ CD19+ CLL cells | 100 nM | 24 hours | Obatoclax in combination with VSV synergistically induced cell death in primary CLL cells, significantly increasing cell mortality. | PMC2997588 |
BxPC-3 | 0–2.5 μM | 24 hours | Obatoclax alone or in combination with TRAIL significantly enhanced apoptosis in BxPC-3 cells, as evidenced by increased Annexin V labeling, accompanied by activation of caspase-8, -9, and -3 and cleavage of Bid. | PMC2948485 |
PANC-1 | 0–2.5 μM | 24 hours | Obatoclax alone or in combination with TRAIL significantly enhanced apoptosis in PANC-1 cells, as evidenced by increased Annexin V labeling, accompanied by activation of caspase-8, -9, and -3 and cleavage of Bid. | PMC2948485 |
Caco-2 | 0.33, 1 μM, 3.3 μM | 24 hours | Evaluate the inhibitory effect of Obatoclax on clinical SARS-CoV-2 isolate infections | PMC8843317 |
Calu-3 | 0.33, 1 μM, 3.3 μM | 24 hours | Evaluate the inhibitory effect of Obatoclax on clinical SARS-CoV-2 isolate infections | PMC8843317 |
CHLA05-ATRT | 40 nM | 24 hours | To evaluate the effect of Obatoclax on apoptosis and oxidative stress, results showed that Obatoclax significantly induced oxidative stress and apoptosis. | PMC9050713 |
CHLA02-ATRT | 40 nM | 24 hours | To evaluate the effect of Obatoclax on apoptosis and oxidative stress, results showed that Obatoclax significantly induced oxidative stress and apoptosis. | PMC9050713 |
BT37 | 40 nM | 24 hours | To evaluate the effect of Obatoclax on apoptosis and oxidative stress, results showed that Obatoclax significantly induced oxidative stress and apoptosis. | PMC9050713 |
CHLA06-ATRT | 40 nM | 24 hours | To evaluate the effect of Obatoclax on apoptosis and oxidative stress, results showed that Obatoclax significantly induced oxidative stress and apoptosis. | PMC9050713 |
BT-12 | 40 nM | 24 hours | To evaluate the effect of Obatoclax on apoptosis and oxidative stress, results showed that Obatoclax significantly induced oxidative stress and apoptosis. | PMC9050713 |
H69 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
H1963 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
H196 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
DMS79 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
H526 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
H82 | 200 nM | 24 hours | Synergistic growth inhibition of SCLC cells and reduction of MCL-1 expression | PMC8285499 |
CT26 cells | 10 µM or 30 µM | 24 hours | To evaluate the inhibitory effect of Obatoclax on the migration of CT26 cells. Results showed that Obatoclax significantly inhibited the migration of CT26 cells at concentrations as low as 0.01 µM. | PMC10981831 |
IPSC-derived neurons with P525L FUS-eGFP | 10 nM | 24 hours | Assessed p62 protein levels and found that obatoclax reduced p62 levels, ameliorating defects in protein homeostasis. | PMC10527391 |
IPSC-derived neurons with P525L FUS-eGFP | 10 nM | 24 hours | Quantified cytoplasmic FUS levels via immunostaining and found that obatoclax significantly reduced cytoplasmic FUS levels. | PMC10527391 |
IPSC-derived neurons with P525L FUS-eGFP | 1, 10, 100, 1000, 10000 nM | 24 hours | Assessed cell viability and found that obatoclax at 10 nM significantly reduced the formation of FUS-eGFP-positive stress granules. | PMC10527391 |
Human melanoma cells (Mel-RM and MM200) | 100 nM to 1 μM | 24 or 48 hours | Obatoclax as a single agent at nanomolar concentrations was relatively ineffective in inducing apoptosis, but when combined with ER stress inducers like tunicamycin or thapsigargin, it markedly enhanced apoptotic cell death. | PMC2735806 |
CT26 cells | 30 µM to 0.3 µM | 24, 48, and 72 hours | To evaluate the inhibitory effect of Obatoclax on the proliferation of CT26 cells. Results showed that Obatoclax significantly inhibited the growth of CT26 cells at lower concentrations. | PMC10981831 |
KG-1 | 0.5, 1, 2.5, 5, 10 μM | 24-72 hours | Obatoclax inhibited KG-1 cell growth and induced apoptosis. | PMC4096127 |
OCI-AML3 | 0.5, 1, 2.5, 5, 10 μM | 24-72 hours | Obatoclax inhibited OCI-AML3 cell growth and induced apoptosis, accompanied by S/G2 cell cycle arrest. | PMC4096127 |
U937 | 0.5, 1, 2.5, 5, 10 μM | 24-72 hours | Obatoclax inhibited U937 cell growth and induced apoptosis, accompanied by cytochrome C release. | PMC4096127 |
HL-60 | 0.5, 1, 2.5, 5, 10 μM | 24-72 hours | Obatoclax inhibited HL-60 cell growth and induced apoptosis, accompanied by Bak release from Mcl-1 and Bim release from Bcl-2/Mcl-1. | PMC4096127 |
Reh cells | 100 nM | 48 h | GX15-070 induces LC3 conversion and caspase-3 cleavage in Reh cells, indicating apoptosis and autophagy. | PMC3032343 |
Jurkat cells | 100 nM | 48 h | GX15-070 induces LC3 conversion and caspase-3 cleavage in Jurkat cells, indicating apoptosis and autophagy. | PMC3032343 |
HSB-2 cells | 100 nM | 48 h | GX15-070 induces LC3 conversion and caspase-3 cleavage in HSB-2 cells, indicating apoptosis and autophagy. | PMC3032343 |
Molt-4 cells | 100 nM | 48 h | GX15-070 induces LC3 conversion and p62 degradation in Molt-4 cells, indicating autophagic cell death. | PMC3032343 |
CCRF-CEM (CEM) T-ALL cells | 100 nM | 48 h | GX15-070 induces caspase-3 and PARP cleavage, increases the Annexin V-positive population, indicating apoptosis. Additionally, GX15-070 induces LC3 conversion and p62 degradation, markers of autophagic cell death. | PMC3032343 |
Mouse embryonic fibroblasts (WT and DKO) | 500 nM | 48 hours | Obatoclax-induced apoptosis is dependent on BAX/BAK, but loss of BAX/BAK fails to rescue cells | PMC3032298 |
H1975 NSCLC cells | 500 nM | 48 hours | Obatoclax induces BAK activation and mitochondrial outer membrane permeabilization | PMC3032298 |
KMCH cells | 400 nM and above | 48 hours | Inhibition of colony formation | PMC2831099 |
BDEneu cells | 200 nM | 48 hours | Inhibition of colony formation, induction of apoptosis | PMC2831099 |
Mz-ChA-1 cells | 5-100 nM | 48 hours | Inhibition of colony formation, induction of apoptosis | PMC2831099 |
HuCCT-1 cells | 5-100 nM | 48 hours | Inhibition of colony formation, induction of apoptosis | PMC2831099 |
Melanocytes | 1 μM | 48 hours | Obatoclax did not induce significant apoptotic cell death in melanocytes (<10% apoptotic cells). | PMC2735806 |
WiDr | 0~400 nM | 48 hours | Obatoclax significantly reduced cell viability with an IC50 of 231.04±2.01 nM | PMC7084590 |
LoVo | 0~400 nM | 48 hours | Obatoclax significantly reduced cell viability with an IC50 of 283.82±3.46 nM | PMC7084590 |
HCT 116 | 0~400 nM | 48 hours | Obatoclax significantly reduced cell viability with an IC50 of 89.96±1.68 nM | PMC7084590 |
DLD-1 | 0~400 nM | 48 hours | Obatoclax significantly reduced cell viability with an IC50 of 257.19±1.46 nM | PMC7084590 |
Caco-2-hACE2 | 330 nM | 72 hours | Evaluate the inhibitory effect of Obatoclax on SARS-CoV-2 pseudovirus entry | PMC8843317 |
A549-hACE2 | 330 nM | 72 hours | Evaluate the inhibitory effect of Obatoclax on SARS-CoV-2 pseudovirus entry | PMC8843317 |
Calu-3-hACE2 | 330 nM | 72 hours | Evaluate the inhibitory effect of Obatoclax on SARS-CoV-2 pseudovirus entry | PMC8843317 |
HEK293T-hACE2 | 330 nM | 72 hours | Evaluate the inhibitory effect of Obatoclax on SARS-CoV-2 pseudovirus entry | PMC8843317 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Fischer 344 rats | Rat cholangiocarcinoma model | Intravenous injection | 1.5 mg/kg | Once daily for 5 consecutive days | Evaluate the anti-tumor effect of Obatoclax in vivo, results showed significant reduction in tumor size and prolonged survival | PMC2831099 |
Nude mice | Subcutaneous xenograft model of K1 cells | Subcutaneous injection | 10 mg/kg/day (single agent) or 20 mg/kg/day (combination therapy) | Once daily for 21 days | Obatoclax alone or in combination with Vemurafenib significantly inhibited the growth of subcutaneous xenografts of K1 cells, and the tumor volume of the combination therapy group was significantly smaller than that of the single-agent treatment group. | PMC5381260 |
BALB/c mice | CT26-Luc2 colorectal liver metastasis model | Intravenous injection | 2 mg/kg or 5 mg/kg | Once daily for 13 days | To evaluate the inhibitory effect of Obatoclax on colorectal liver metastasis. Results showed that Obatoclax significantly inhibited liver metastasis at doses of 2 mg/kg and 5 mg/kg. | PMC10981831 |
Nude mice | H82 SCLC xenograft model | Intraperitoneal injection | 3 mg/kg | Every 3 days for 21 days | Significant inhibition of SCLC tumor growth and reduction of Ki-67 proliferation marker | PMC8285499 |
SCID mice | A20 lymphoma model | Intraperitoneal injection | 3 mg/kg/day | Five consecutive days | Obatoclax in combination with VSV significantly inhibited A20 lymphoma tumor growth in vivo, reducing tumor volume by 80%. | PMC2997588 |
Nu/Nu mice | CHLA06-ATRT and BT37 orthotopic xenograft models | IP or oral | Obatoclax 6 mg/kg IP or 10 mg/kg oral, TAK-228 6 mg/kg oral | Once a week, continuous treatment | To evaluate the effect of Obatoclax and TAK-228 combination therapy on tumor growth and survival, results showed that combination therapy significantly slowed tumor growth and extended median survival. | PMC9050713 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT01150656 | - | Completed | - | - | |
NCT00438178 | Hematological Malignancies | Phase 1 | Completed | - | United States, District of Col... More >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00360035 | Myelofibrosis | Phase 2 | Completed | - | United States, District of Col... More >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Florida James A. Haley Veterans Hospital Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Illinois The University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts University of Massachusetts Medical Center Worcester, Massachusetts, United States, 01655 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00724841 | Metastatic Melanoma | Phase 1 Phase 2 | Terminated(Study terminated pr... More >>ematurely due to financial contraints.) Less << | - | United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less << |
NCT00521144 | Recurrent Small Cell Lung Canc... More >>er Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 Phase 2 | Completed | - | United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT01238146 | Extranodal Marginal Zone B-cel... More >>l Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Less << | Phase 1 Phase 2 | Withdrawn(No patients accrued.... More >>) Less << | - | United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less << |
NCT00521144 | - | Completed | - | - | |
NCT00719901 | Refractory Multiple Myeloma ... More >> Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma Less << | Phase 1 Phase 2 | Terminated(This trial was term... More >>inated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.) Less << | - | United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT00413114 | Myelodysplastic Syndromes | Phase 2 | Completed | - | - |
NCT00405951 | Lung Cancer | Phase 1 Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic College of Medicine Scottsdale, Arizona, United States, 85259 United States, California Tower Oncology Beverly Hills, California, United States, 90210 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007 United States, Florida H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Maryland University of Maryland Baltimore, Maryland, United States, 21201 MedStar Research Institute Baltimore, Maryland, United States, 21225 United States, Texas Arlington Cancer Center Arlington, Texas, United States, 76012 Less << |
NCT01563601 | Extensive-stage Small Cell Lun... More >>g Cancer Less << | Phase 3 | Withdrawn(Business Decision) | January 2018 | - |
NCT00407303 | Mantle-Cell Lymphoma | Phase 1 Phase 2 | Completed | - | United States, Georgia ... More >> NW Georgia Oncology Centers Marietta, Georgia, United States, 30060 United States, Illinois Northwestern University Feinberg School of Medicine Chicago, Illinois, United States, 60611 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Roswell Park Medical Center Buffalo, New York, United States, 14263 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 Less << |
NCT00359892 | Hodgkin's Lymphoma | Phase 2 | Completed | - | United States, Texas ... More >> MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT00918931 | - | Terminated | - | - | |
NCT00719901 | - | Terminated(This trial was term... More >>inated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.) Less << | - | - | |
NCT00612612 | B-cell Chronic Lymphocytic Leu... More >>kemia Leukemia Prolymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia Less << | Phase 1 | Terminated | - | United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less << |
NCT00918931 | Leukemia Syst... More >>emic Mastocytosis Less << | Phase 2 | Terminated | - | United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT00427856 | Lymphoma, Follicular | Phase 2 | Completed | - | United States, New Jersey ... More >> The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Less << |
NCT00600964 | Chronic Lymphocytic Leukemia | Phase 1 | Completed | - | United States, California ... More >> University of CA- San Diego La Jolla, California, United States, 92093 United States, District of Columbia Lombardi Cancer Center Washington, District of Columbia, United States, 20007 United States, Pennsylvania Milton S Hershey Medical Center Penn State Cancer Institute Hershey, Pennsylvania, United States, 17033 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT00933985 | Acute Leukemias of Ambiguous L... More >>ineage Acute Undifferentiated Leukemia Angioimmunoblastic T-cell Lymphoma Blastic Phase Chronic Myelogenous Leukemia Childhood Burkitt Lymphoma Childhood Chronic Myelogenous Leukemia Childhood Diffuse Large Cell Lymphoma Childhood Immunoblastic Large Cell Lymphoma Childhood Nasal Type Extranodal NK/T-cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Noncutaneous Extranodal Lymphoma Peripheral T-cell Lymphoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Anaplastic Large Cell Lymphoma Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent/Refractory Childhood Hodgkin Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Relapsing Chronic Myelogenous Leukemia Small Intestine Lymphoma Unspecified Childhood Solid Tumor, Protocol Specific Less << | Phase 1 | Terminated | - | - |
NCT00684918 | AML | PHASE2 | COMPLETED | 2025-12-09 | Northwestern University, Chica... More >>go, Illinois, 60611, United States|The University of Iowa, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center Research Institute, Westwood, Kansas, 66205, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, 48106, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Michigan State University - Breslin Cancer Center, Lansing, Michigan, 48910, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, 10011, United States|Legacy Emanuel Hospital & Health Center, Portland, Oregon, 97210, United States|Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, 17033, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, 98101, United States|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada Less << |
NCT00538187 | Adult Non-Hodgkin Lymphoma ... More >> Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Less << | Phase 1 | Terminated | - | United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 Less << |
NCT00682981 | Extensive-stage Small Cell Lun... More >>g Cancer Less << | Phase 1 Phase 2 | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.15mL 0.63mL 0.32mL |
15.75mL 3.15mL 1.58mL |
31.51mL 6.30mL 3.15mL |